SAGE Therapeutics, Inc. Forecast, price target & analysts
SAGE Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
SAGE Therapeutics, Inc. Classifications & Recommendation:
SAGE Therapeutics, Inc. Price Target
| Target Price | $8.13 |
| Price | $7.19 |
| Potential |
13.12%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target SAGE Therapeutics, Inc. 2026 .
The average SAGE Therapeutics, Inc. target price is $8.13.
This is
13.12%
register free of charge
$12.00
66.90%
register free of charge
$5.00
30.46%
register free of charge
|
|
| A rating was issued by 17 analysts: 3 Analysts recommend SAGE Therapeutics, Inc. to buy, 14 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the SAGE Therapeutics, Inc. stock has an average upside potential 2026 of
13.12%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 41.24 | 81.04 |
| 52.30% | 96.51% | |
| EBITDA Margin | -992.94% | -343.83% |
| 57.50% | 65.37% | |
| Net Margin | -980.51% | -270.99% |
| 52.66% | 72.36% |
17 Analysts have issued a sales forecast SAGE Therapeutics, Inc. 2025 . The average SAGE Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an SAGE Therapeutics, Inc. EBITDA forecast 2025. The average SAGE Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 SAGE Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average SAGE Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -6.59 | -3.58 |
| 27.18% | 45.68% | |
| P/E | negative | |
| EV/Sales | negative |
10 Analysts have issued a SAGE Therapeutics, Inc. forecast for earnings per share. The average SAGE Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the SAGE Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
SAGE Therapeutics, Inc....
Current SAGE Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Feb 12 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 12 2025 |
| Scotiabank | Locked ➜ Locked | Locked | Feb 12 2025 |
| Wedbush | Locked ➜ Locked | Locked | Feb 12 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 12 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Jan 02 2025 |
| Stifel | Locked ➜ Locked | Locked | Dec 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Scotiabank: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Wedbush: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Jan 02 2025 |
|
Locked
Stifel: Locked ➜ Locked
|
Dec 16 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
